Ascentage Pharma

Last updated: 04.12.2019


Ascentage Pharma is a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases. The company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death.

Ascentage Pharma has built a pipeline of eight drug candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. The company has conducted 28 Phase I/II clinical trials to evaluate the eight products in the United States, Australia and China, developing the potential therapies as a single agent or in combination.



218 Xinghu Street, Building B7, 7th Floor, Suzhou Industrial Park, Suzhou, Jiangsu, 215000 Chin

Tel: +86 512 85557777



We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here